Recent studies have demonstrated that pretreatment with ALA can ameliorate LPS-induced ALI by not only reducing the release of IL-1β cytokines from apoptosis cells but also inhibiting the activation of Pyrin inflammasome-driven macrophage sepsis [132, 133], offering a potential therapeutic option for managing ALI/ARDS through enteral nutrition. The gene discussed is MEFV; the disease is acute respiratory distress syndrome.